Mesenchymal Stem Cell Supernatant With Targeted Nerve Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic agents for nerve disorders, particularly those using mesenchymal stem cell culture supernatants, require improvement in efficacy.
Innovation Solution
A therapeutic agent combining mesenchymal stem cell culture supernatants with nerve stimulation, applied at specific sites and timings, including before and after administration, enhances therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cell culture supernatant is administered alone, then basic therapeutic effect is achieved, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines mesenchymal stem cell culture supernatant administration with nerve stimulation therapy into a unified treatment protocol. The culture supernatant is administered at specific time points (before, during, and after stimulation) to synergistically enhance the therapeutic effect of nerve stimulation, thereby improving overall therapeutic efficacy while maintaining a coordinated treatment approach
Solution Approach 2:
The patent applies nerve stimulation before administering the culture supernatant to prepare the nerve tissue for enhanced receptivity. This preliminary stimulation activates neural pathways and increases blood flow to the target area, creating optimal conditions for the subsequent culture supernatant administration to maximize therapeutic effect
2Reliability
If culture supernatant is administered without optimized timing, then treatment is simpler, but therapeutic effect is reduced
Solution Approach 1:
The patent implements periodic administration of culture supernatant at strategically determined time intervals relative to nerve stimulation sessions. The supernatant is administered before stimulation to prepare neural tissue, during stimulation to maintain therapeutic levels, and after stimulation to sustain repair processes, creating a rhythmic treatment pattern that maximizes efficacy
Solution Approach 2:
The patent administers culture supernatant before nerve stimulation to pre-condition the neural tissue and enhance its responsiveness to upcoming stimulation. This preliminary administration ensures that bioactive factors are present in the target tissue before stimulation begins, optimizing the synergistic effect
3Reliability
If stimulation is applied to non-specific sites, then treatment application is easier, but therapeutic precision is reduced
Solution Approach 1:
The patent applies nerve stimulation to specifically identified injury sites rather than generalized areas. The culture supernatant is administered locally at the injury site to concentrate therapeutic factors where needed, and stimulation is targeted to specific neural pathways involved in the injury, ensuring precise therapeutic action at the affected location
Data Source
AI summary
The present invention addresses the problem of providing a therapeutic agent that is more efficacious for treating nerve disorders, said therapeutic agent comprising a culture supernatant of mesenchymal stem cells. The present invention provides a therapeutic agent for nerve disorders, said therapeutic agent comprising a culture supernatant of mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells and being to be used together with stimulation of patient's nerves, wherein the stimulation is preferentially provided to one or more sites selected from the group consisting of a site of nerve damage, an area surrounding a site of nerve damage, and a site compensating for the function of a site of nerve damage.